×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FGEN – fibrogen, inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/30
02:02 am
fgen
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/28
07:00 am
fgen
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
High
Report
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
3/22
02:04 am
fgen
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/18
12:11 pm
fgen
FibroGen, Inc. (NASDAQ: FGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
FibroGen, Inc. (NASDAQ: FGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/17
08:20 pm
fgen
FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript [Seeking Alpha]
High
Report
FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript [Seeking Alpha]
3/17
04:16 pm
fgen
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
High
Report
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
3/17
04:05 pm
fgen
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
High
Report
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
3/14
02:00 am
fgen
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/31
06:00 am
fgen
Form 8-K FIBROGEN INC For: Mar 28
Low
Report
Form 8-K FIBROGEN INC For: Mar 28
3/28
05:20 pm
fgen
Form 8-K FIBROGEN INC For: Mar 28
Low
Report
Form 8-K FIBROGEN INC For: Mar 28
3/25
09:00 am
fgen
Form 4 FIBROGEN INC For: Mar 24 Filed by: Wettig Thane
Medium
Report
Form 4 FIBROGEN INC For: Mar 24 Filed by: Wettig Thane
3/24
09:00 am
fgen
Form 4 FIBROGEN INC For: Mar 20 Filed by: Schoeneck James A
Medium
Report
Form 4 FIBROGEN INC For: Mar 20 Filed by: Schoeneck James A
3/17
04:16 pm
fgen
Form 10-K FIBROGEN INC For: Dec 31
High
Report
Form 10-K FIBROGEN INC For: Dec 31
3/17
04:10 pm
fgen
Form 8-K FIBROGEN INC For: Mar 12
High
Report
Form 8-K FIBROGEN INC For: Mar 12
3/7
07:04 pm
fgen
Form 4 FIBROGEN INC For: Mar 06 Filed by: Wettig Thane
Medium
Report
Form 4 FIBROGEN INC For: Mar 06 Filed by: Wettig Thane
3/7
07:02 pm
fgen
Form 4 FIBROGEN INC For: Mar 06 Filed by: DeLucia David
Medium
Report
Form 4 FIBROGEN INC For: Mar 06 Filed by: DeLucia David
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/8
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
20.6%
9/18 Form 4 FIBROGEN INC For: Sep 17 Filed by: Cotroneo Pat 18.0%
5/9 FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program 13.5%
3/19 FibroGen Inc (NASDAQ: FGEN) had its price target lowered by analysts at Citigroup Inc from $65.00 to $51.00. They now have a "buy" rating on the stock. 12.5%
3/23 Form 4 FIBROGEN INC For: Mar 19 Filed by: KEARNS THOMAS F JR 12.4%
3/26 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 7.7%
8/26 Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive 7.4%
2/5 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
6/14 Form 4 FIBROGEN INC For: Jun 12 Filed by: Yu K Peony 5.7%
11/14 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 5.3%
9/18 Form 4 FIBROGEN INC For: Sep 17 Filed by: Cotroneo Pat 18.0%
5/9 FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program 13.5%
3/19 FibroGen Inc (NASDAQ: FGEN) had its price target lowered by analysts at Citigroup Inc from $65.00 to $51.00. They now have a "buy" rating on the stock. 12.5%
3/23 Form 4 FIBROGEN INC For: Mar 19 Filed by: KEARNS THOMAS F JR 12.4%
3/26 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 7.7%
8/26 Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive 7.4%
2/5 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
6/14 Form 4 FIBROGEN INC For: Jun 12 Filed by: Yu K Peony 5.7%
11/14 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 5.3%
TOP News Decliners
5/9
Form 8-K FIBROGEN INC For: May 09
-27.0%
11/11 FibroGen Inc (NASDAQ: FGEN) had its "positive" rating re-affirmed by analysts at Mizuho. They now have a $72.00 price target on the stock, up previously from $65.00. -15.5%
3/18 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -12.1%
3/2 Form S-3ASR FIBROGEN INC -8.6%
11/4 FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 -7.5%
9/23 Form 4 FIBROGEN INC For: Sep 19 Filed by: Chung Christine -6.8%
8/14 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. -6.6%
8/8 FibroGen Reports Second Quarter 2019 Financial Results -6.5%
5/6 FibroGen to Report First Quarter 2019 Financial Results -6.0%
3/19 Form 4 FIBROGEN INC For: Mar 06 Filed by: Chung Christine -5.1%
11/11 FibroGen Inc (NASDAQ: FGEN) had its "positive" rating re-affirmed by analysts at Mizuho. They now have a $72.00 price target on the stock, up previously from $65.00. -15.5%
3/18 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -12.1%
3/2 Form S-3ASR FIBROGEN INC -8.6%
11/4 FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 -7.5%
9/23 Form 4 FIBROGEN INC For: Sep 19 Filed by: Chung Christine -6.8%
8/14 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. -6.6%
8/8 FibroGen Reports Second Quarter 2019 Financial Results -6.5%
5/6 FibroGen to Report First Quarter 2019 Financial Results -6.0%
3/19 Form 4 FIBROGEN INC For: Mar 06 Filed by: Chung Christine -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: